Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
NCT ID NCT07745296
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether giving targeted therapies that match specific genetic abnormalities in a person's tumor can delay or prevent biliary tract cancer from coming back after surgery. Participants will have their tumor tested for certain markers, and if found, they will be randomly assigned to receive either the targeted therapy or standard chemotherapy. The study aims to see if this precision medicine approach is better than the current standard of care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Targeted therapies (futibatinib, ivosidenib, zanidatamab) combined with or replacing standard chemotherapy (capecitabine)
- What this could lead to
- If successful, this approach could offer a more personalized treatment option for biliary tract cancer, potentially delaying or preventing cancer recurrence after surgery.
- What could go wrong
- The trial is large and phase 3, but targeted therapies may not work for all patients, and side effects are possible. The benefit over standard chemotherapy is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine help fight Hard-to-Treat cancers?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can a dual immune booster plus chemo shrink hard-to-treat bile duct tumors?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- New hope for bile duct cancer: drug duo targets tough tumors
- Radiation plus immunotherapy shows promise in bile duct cancer trial